Luisa Foltran et al., Prognostic role of KRAS, NRAS, BRAF and PIK3CA mutations in advanced colorectal cancer. Future Oncology

//Luisa Foltran et al., Prognostic role of KRAS, NRAS, BRAF and PIK3CA mutations in advanced colorectal cancer. Future Oncology

Luisa Foltran et al., Prognostic role of KRAS, NRAS, BRAF and PIK3CA mutations in advanced colorectal cancer. Future Oncology

Luisa Foltran1,2, Giovanna De Maglio3, Nicoletta Pella1, Paola Ermacora1, Giuseppe Aprile1, Elena Masiero3, Mariella Giovannoni1, Emiliana Iaiza1, Giovanni Gerardo Cardellino1, Stefania Eufemia Lutrino1, Micol Mazzer1,4, Manuela Giangreco5, Federica Edith Pisa5, Stefano Pizzolitto3 & Gianpiero Fasola1

1Department of Oncology, University Hospital ‘S Maria della Misericordia’, Piazzale S Maria della Misericordia 15, Udine, Italy
2Department of Oncology, General Hospital ‘S Maria degli Angeli’, Via Montereale 24, Pordenone, Italy
3Department of Pathology, University Hospital ‘S Maria della Misericordia’, Piazzale S Maria della Misericordia 15, Udine, Italy
4Hospice ‘Casa dei Gelsi’, ULSS 9, Via Fossagera 4/c, Treviso, Italy
5Institute of Hygiene & Clinical Epidemiology, University Hospital ‘S Maria della Misericordia’, Piazzale S Maria della Misericordia 15, Udine, Italy

Abstract

Aim: To explore the prognostic value of extended mutational profiling for metastatic colorectal cancer (mCRC). Materials & methods: We retrospectively reviewed survival results of 194 mCRC patients that were assigned to four molecular subgroups: BRAF mutated; KRAS mutated codons 12-13 only; any of KRAS codons 61-146, PIK3CA or NRAS mutations and all wild-type. Point mutations were investigated by pyrosequencing. Results: BRAF (5.2%) and KRAS 12-13 (31.9%) mutations were associated with poorer survival (HR 2.8 and 1.76, respectively). Presenting with right-sided colon cancer, not resected primary tumor, WBC >10 × 109/l, receiving less chemotherapy or no bevacizumab were all associated with inferior outcome. The all-wild-type subgroup (39.2%) reported the longest survival. Conclusion: Extended mutational profile combined with clinical factors may impact on survival in mCRC.

Read the complete publication at this link

Autori
Prodotti
Richiedi informazioni

Inserisci i tuoi dati, ti contatteremo al più presto.

Acconsento al trattamento della privacy



2017-08-08T15:29:58+00:00